26 11月 2025 by admin in UncategorizedComments Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
19 11月 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer
17 11月 2025 by admin in UncategorizedComments NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
23 10月 2025 by admin in UncategorizedComments Sail Biomedicines Appoints Martin Mackay, Ph.D., to Its Board of Directors
16 10月 2025 by admin in UncategorizedComments NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
16 10月 2025 by admin in UncategorizedComments Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment- Refractory Rheumatoid Arthritis (RA)
08 10月 2025 by admin in UncategorizedComments Zenas BioPharmand InoCare Pharma Anounce License Agrement Granting Zenas Rights for Thre Autoimune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
07 10月 2025 by admin in UncategorizedComments Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
22 9月 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces $60 Million Series B Financing
10 9月 2025 by admin in UncategorizedComments Design Therapeutics Appoints Justin Gover to Board of Directors
02 9月 2025 by admin in UncategorizedComments Zenas BioPharmand Royalty Pharma Enter into Obexelimab Funding Agrement for up to $30 Milion $300 Million
02 9月 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
21 8月 2025 by admin in UncategorizedComments Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
08 7月 2025 by admin in UncategorizedComments U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for Gastric Cancer
08 7月 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate
30 6月 2025 by admin in UncategorizedComments Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
26 6月 2025 by admin in UncategorizedComments Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia
16 6月 2025 by admin in UncategorizedComments NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
11 6月 2025 by admin in UncategorizedComments Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
21 4月 2025 by admin in UncategorizedComments Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
17 4月 2025 by admin in UncategorizedComments Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
17 4月 2025 by admin in UncategorizedComments Adicet Bio Appoints Michael Grissinger to the Board of Directors
07 4月 2025 by admin in UncategorizedComments Zenas BioPharma Apoints Haley Laken, Ph.D., as Chief Scientific Oficer April 7, 2025
07 4月 2025 by admin in UncategorizedComments Sail Biomedicines Appoints Laura Sepp-Lorenzino, Ph.D., to Its Board of Directors
20 3月 2025 by admin in UncategorizedComments Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
17 3月 2025 by admin in UncategorizedComments Zenas BioPharma Apoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Oficer and Chief Medical Officer
10 1月 2025 by admin in UncategorizedComments Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD
07 1月 2025 by admin in UncategorizedComments Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe
07 1月 2025 by admin in UncategorizedComments Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate
06 1月 2025 by admin in UncategorizedComments Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
06 1月 2025 by admin in UncategorizedComments Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors
19 12月 2024 by admin in UncategorizedComments Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
18 12月 2024 by admin in UncategorizedComments Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer
10 12月 2024 by admin in UncategorizedComments NextCure Announces Acceptance of IND Application for LNCB74
26 11月 2024 by admin in UncategorizedComments Oricell Therapeutics Receives China NMPA IND Clearance for MSLN/Claudin 18.2 Dual CAR-T Therapy for Solid Tumors
26 11月 2024 by admin in UncategorizedComments Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid Tumors
